antimetabolites Flashcards

1
Q

Anti-metabolites are generally more effective when cell is active in the ______-phase of the cell cycle.

Many are structural analogs of naturally occurring substances found within the cell.

Anti-metabolites act by either (2)

A

Anti-metabolites are generally more effective when cell is active in the S-phase of the cell cycle.

Many are structural analogs of naturally occurring substances found within the cell.

Anti-metabolites act by either (1) falsely incorporating into DNA or RNA or (2) by competing for binding sites on enzymes involved in DNA synthesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anti-metabolites (4)

A
  1. methotrexate
  2. cytarabine
  3. 5-fluorouracil
  4. gemcitabine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Methotrexate (MTX) is a _______ antimetabolite inhibiting DNA synthesis.

It competitively binds to dihydrofolate reductase (DHFR), which is responsible for production of reducted folates necessary for one-carbon transfers and thus _______.

MTX also binds to thymidylate synthetase, inhibiting synthesis of _______.

A

Methotrexate (MTX) is a folate antimetabolite inhibiting DNA synthesis.

It competitively binds to dihydrofolate reductase (DHFR), which is responsible for production of reducted folates necessary for one-carbon transfers and thus purine synthesis.

MTX also binds to thymidylate synthetase, inhibiting synthesis of thymidylate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MTX binding to DHFR inhibits conversion of folic acid to _________ leading to _______ pools of purine nucleotides and thymidylate.

A

MTX binding to DHFR inhibits conversion of folic acid to tetrahydrofolate (FH4), leading to decreased pools of purine nucleotides and thymidylate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Major pharmacokinetic points to remember:

  • MTX binds to _______, leading to drug interactions;
  • MTX is very _______ and readily distributes into 3rd space fluid, so it can accumulate in ______ and slowly leak back into the systemic circulation (depot effect);
  • MTX at high doses can cross into ____
A
  • MTX binds to albumin, leading to drug interactions;
  • MTX is very hydrophilic and readily distributes into 3rd space fluid, so it can accumulate in effusions and slowly leak back into the systemic circulation (depot effect);
  • MTX at high doses can cross into CNS.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MTX in active transport vs passive dissuion

A
  1. at low concentrations active transport predominates but At high doses the active transport mechanism is overwhelmed, so passive diffusion becomes the main mechanism for cell entry in the CNS.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

There are multiple metabolic steps of MTX.

The most important is ___________, leading to the form that is retained in cell for longer periods of time due to slower dissociation from DHFR enzyme.

This form also inhibits ______ synthase and is not easily removed from the cell.

  1. the formation if DAMPA by intestinal bacteria
A

There are multiple metabolic steps of MTX.

The most important is polyglutamation, leading to the polyglutamated form that is retained in cell for longer periods of time due to slower dissociation from DHFR enzyme.

This polyglutamated form also inhibits thymidylate synthase and is not easily removed from the cell.

  1. the formation if DAMPA by intestinal bacteria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Majority of MTX elimination occurs via ______, therefore dose adjustment is necessary in those with ______, however there is some elimination through the _____ and explain that patients with ______ may have increased toxicity because of delayed clearance.

A

Majority of MTX elimination occurs via kidneys, therefore dose adjustment is necessary in those with reduced renal function. however there is some elimination through the biliary and explain that patients with intestinal obstruction may have increased toxicity because of delayed clearance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

toxicity of MTX include

  1. low dose:
  2. High dose:

how can toxicity be prevented?

A
  1. low dose: myelosuppression with possible nephrotoxicity
  2. High dose: myelosuppression and nephrotoxicity from precipitation in renal tubules

A major side effect of MTX is renal toxicity. At high doses, MTX precipitates into renal tubules, causing direct damage, particularly in an acidic environment. This toxicity can be prevented by alkalinization of the urine and hydration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

rescue if there is MTX tox.

A

leucovorin- administration is based on dosage levels b/c there is competition and at increased doses of MTX, leucovorin also increases but you need to avoid excessive leucovorin doses due its ability to block anti-tumor activity of MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In addition to nephrotoxicity, MTX will have other SE including to the GI such as N/V, myelosupression, and hepatoxicity.

there is one that SE that needs to be watched out just in case before starting treatment?

A

pneumonitis, the effusion must be drained before treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

can MTX be given into the CSF to clear malignant meningitis?

A

yep and thus there can be some neurotoxicity associated with leukoencephalopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

leucovorin

A

provides reduced folates back into the cellular pool and thus bypasses blockade of DHFR and allowing DNA synthesis to occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

why does leucoveorin given 24 hr after MTX infusion?

A

MTX affects the bone marrow and GI tract at very low levels and will cause irreversible damage so the timing of of leucovorin is critical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MTX has multiple drug interactions:

  • Drugs that are _________ can “knock” methotrexate off albumin, increase plasma levels, and therefore increase toxicity, and vice versa.
  • Concomitant _____ drugs should be avoided.
  • L-asparaginase prevents cells from entering ___-phase and can therefore _____ effects of methotrexate.
A
  • Drugs that are also highly protein bound can “knock” methotrexate off albumin, increase plasma levels, and therefore increase toxicity, and vice versa.
  • Concomitant nephrotoxic drugs should be avoided– affect creatinine clearence
  • L-asparaginase prevents cells from entering S-phase and can therefore reduce effects of methotrexate.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

cyatarabine can also be given directly into the CSF

A

yep

17
Q

Cytarabine (Ara-C) is a ______ analog and must undergo conversion to triphosphate and diphosphate forms.

The triphosphate form competitively inhibits DNA ________ by incorporating into DNA, halting chain elongation.

Like other anti-metabolites, cytarabine is most effective in _______

It is a cycle dependent on ____-phase.

It is metabolized by ________

A

Cytarabine (Ara-C) is a pyrimidine analog and must undergo conversion to triphosphate and diphosphate forms.

The triphosphate form competitively inhibits DNA polymerase by incorporating into DNA, halting chain elongation.

Like other anti-metabolites, cytarabine is most effective in actively proliferating cells.

It is a cycle dependent on S-phase.

It is metabolized by deoxycytidine kinase

18
Q

Cytarabine is only available as an _______. Ara-C is inactivated via deamination in the ____ by cytidine deaminase. Metabolites are cleared through _____ and ____mechanisms. Some inactive metabolites may cause toxicity if they accumulate.

A

Cytarabine is only available as an intravenous formulation. Ara-C is inactivated via deamination in the gut by cytidine deaminase. Metabolites are cleared through hepatic and renal mechanisms. Some inactive metabolites may cause toxicity if they accumulate.

19
Q

Most chemo agents do not cross the BBB, so cytarabine, with MTX, is the backbone of treatment for

A

ALL

20
Q

Cytarabine toxicity

  1. distributes into tears and may cause ________
  2. major dose-limiting toxicity is _____, especially neutropenia but also thrombocytopenia, even at low doses
  3. in younger patients it can cause _____ syndrome
  4. due to its target in S-phase it can also cause _______
  5. rare symptom is _______ syndrome
  6. rare pulmonary SE includes ____________
A
  1. distributes into tears and may cause chemical conjunctivitis
  2. major dose-limiting toxicity is myelosuppression, especially neutropenia but also thrombocytopenia, even at low doses
  3. in younger patients it can cause flu-like syndrome
  4. due to its target in S-phase it can also cause mucositis
  5. rare symptom is hand-foot syndrome
  6. rare pulmonary SE includes noncardiogenic pulmonary edema
21
Q

5-FU is a prodrug, a “false” pyrimidine that inhibits formation of ________ and it is ___phase specific.

Through multiple phosphorylation steps, 5-FU is metabolized to the active metabolite _________, which incorporates into DNA at different sites and inhibits thymidylate synthase.

Metabolites also may falsely incorporate into ____ to inhibit _____ synthesis.

Leucovorin acts to?

A

5-FU is a prodrug, a “false” pyrimidine that inhibits formation of thymidine and it is S-phase specific

Through multiple phosphorylation steps, 5-FU is metabolized to the active metabolite F-dUMP, which incorporates into DNA at different sites and inhibits thymidylate synthase.

Metabolites also may falsely incorporate into RNA to inhibit RNA synthesis.

Leucovorin acts to augment cytotoxic effects of 5-FU (in contrast to its effects on MTX).

22
Q

Since 5-FU undergoes enzymatic degradation, it may be used in patients with some degree of

A

Since 5-FU undergoes enzymatic degradation, it may be used in patients with some degree of renal and/or hepatic dysfunction.

23
Q

5-FU is metabolized by __________. The gene that codes for this enzyme has many polymorphisms. Those deficient in the DPD enzyme level or function may experience increased 5-FU toxicity due to accumulation of metabolites

90% of its doses is cleared in ___ and ____ and it has a short half life of only ________

A

5-FU is metabolized by dihydropyrimidine dehydrogenase (DPD). The gene that codes for this enzyme has many polymorphisms. Those deficient in the DPD enzyme level or function may experience increased 5-FU toxicity due to accumulation of metabolites

90% of its doses is cleared in urine and lungs and it has a short half life of only 10-20 minutes

24
Q

The major dose-limiting toxicity is _________, more common with 5-FU than other anti-metabolite agents. Myelosuppression (neutropenia) can also occur but is less of an issue as compared with other chemo agents. Hand-foot syndrome is more _____with 5-FU than other agents. Neurotoxicity is _____. All 5-FU toxicities are more severe in patients with _____ gene alterations.

Other toxicities include _______, an infrequent effect due to coronary vasospasm. Patients appear to be having MI – treatment is supportive and usually precludes patients from receiving drug again.
___________ can occur so patients must be instructed to wear sunscreen and protective clothing when exposed to sun.
A _______ taste in the mouth can affect nutritional status.
________ can occur with repeated infusions/injections into same vein.

A

The major dose-limiting toxicity is mucositis/diarrhea, more common with 5-FU than other anti-metabolite agents. Myelosuppression (neutropenia) can also occur but is less of an issue as compared with other chemo agents. Hand-foot syndrome is more common with 5-FU than other agents. Neurotoxicity is rare. All 5-FU toxicities are more severe in patients with DPD gene alterations.

Other toxicities include cardiotoxicity, an infrequent effect due to coronary vasospasm. Patients appear to be having MI – treatment is supportive and usually precludes patients from receiving drug again.
Photosensitivity can occur so patients must be instructed to wear sunscreen and protective clothing when exposed to sun.
A metallic taste in the mouth can affect nutritional status.
Phlebitis can occur with repeated infusions/injections into same vein.

25
Q

Gemcitabine is metabolized by cytidine deaminase, with metabolites excreted in the ___

It is important to note that the half life

A

Gemcitabine is metabolized by cytidine deaminase, with metabolites excreted in the urine.

half life changes with infusion time

26
Q

The major dose-limiting toxicity is ________, mainly neutropenia.

Flu-like symptoms and infusion reactions are also among common. Infusions reactions may include (4)

A skin rash can also develop-

A

The major dose-limiting toxicity is myelosuppression, mainly neutropenia. Flu-like symptoms and infusion reactions are also among common. Infusions reactions may include flushing, swelling, headache, and dyspnea.

A skin rash can also develop- maculopapular

27
Q

Gemcitabine is a radiosensitizer, meaning concomitant treatment of tumor cells with gemcitabine makes _________

A

Gemcitabine is a radiosensitizer, meaning concomitant treatment of tumor cells with gemcitabine makes tumor cells more sensitive to the effects of radiation.
Thus, a combination leads to better effects of radiation therapy. Combinations of concurrent chemotherapy and radiation often exploit this radiosensitizing effect.

28
Q

Gemcitabine was the first drug approved on a “clinical benefit response,” and not objective response rates.

It is a _____ analog, a cousin to cytarabine with similar actions and it is ____phase specific

Gemcitabine requires intracellular by _____________activation to triphosphate nucleotide

Incorporation results in termination of ________ by inhibitng DNA polymerases

It may also incorporate into______and alter ______translation

A

Gemcitabine was the first drug approved on a “clinical benefit response,” and not objective response rates.

It is a deoxycytidine analog, a cousin to cytarabine with similar actions and it is S-phase sepcific.

Gemcitabine requires intracellular by deoxycitidine kinase activation to triphosphate nucleotide

Incorporation results in termination of DNA chain elongation by inhibitng DNA polymerases

It may also incorporate into RNA and alter RNA translation.